Targeted Cancer Immune Therapy

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Lustgarten, Joseph (Επιμελητής έκδοσης), Cui, Yan (Επιμελητής έκδοσης), Li, Shulin (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: New York, NY : Springer New York, 2009.
• Θέματα: Medicine.; Cancer research.; Pharmacology.; Biomedicine.; Cancer Research.; Pharmacology/Toxicology.

 Cancer has surpassed heart disease as the number one killer in the world, and standard cancer therapy such as radiation, chemotherapy, and surgery may have reached its plateau in further improving the outcome of treated patients. Biological therapies combined with other treatment approaches may be the next X-factor to greatly extend survival time and improve patients’ quality of life. One of the most developed fields in biological therapy is immune therapy, which has stemmed into many branches due to its significance and the tremendous effort by a large population of scientists. Tumor-targeted antibody therapy has been successfully used for treating some types of tumors, and the first tumor vaccine against ovarian cancer has been developed for clinical application. Targeted Cancer Immune Therapy provides comprehensive coverage of novel immune therapeutic approaches, including cytokine therapy, engineered cell therapy, and the application of tumor-targeted antibodies for generating tumor-specific cell therapy, TLR ligand therapy, and cytokine therapy. In the section "Cytokine Immune Therapy," the authors review relatively new cytokine family members, such as the IL12 family, IL18, IL21, IL24, IL28, and IL29, in regard to the anti-tumor function and application in treating tumors. The strategy for targeting and retaining cytokines in the tumor microenvironment is also reviewed. The section "Cell-based Immune Therapy" focuses on reviewing "state of the art" approaches for engineering potent immune regulatory or effector cells, such as dendritic cells, T cells, and stem cells, for tumor targeting and initiation of tumor specific immune response. In the section "Targeted Immune Therapy," the authors rearticulate antibody therapy for boosting immune response, which includes immunocytokines, "T-body," and tumor targeted CpG ODN. Some or all of these innovative approaches may ultimately become effective future immune therapies for treating malignancy. 

 Cytokine Immune Therapy -- Role of IL12 Family in Regulation of Antitumor Immune Response -- IL-18 in Regulation of Antitumor Immune Response and Clinical Application -- Interleukin-21 and Cancer Therapy -- IL-24 in Regulation of Antitumor Immune Response and in Signaling -- IL-28 and IL-29 in Regulation of Antitumor Immune Response and Induction of Tumor Regression -- Passive and Active Tumor Homing Cytokine Therapy -- Cell-based Immune Therapy -- New Strategies to Improve Tumor Cell Vaccine Therapy -- Modification of Dendritic Cells to Enhance Cancer Vaccine Potency -- Dendritic Cell Vaccines for Immunotherapy of Cancer: Challenges in Clinical Trials -- A “Toll Bridge” for Tumor-Specific T Cells -- Engineering Adult Stem Cells for Cancer Immunotherapy -- Animal Models for Evaluating Immune Responses of Human Effector Cells In Vivo -- Targeted Immune Therapy -- CD40 Stimulation and Antitumor Effects -- Immunocytokines: A Novel Approach to Cancer Immune Therapy -- Immune Escape: Role of Indoleamine 2,3-Dioxygenase in Tumor Tolerance -- Adoptive Transfer of T-Bodies: Toward an Effective Cancer Immunotherapy -- Targeting Toll-Like Receptor for the Induction of Immune and Antitumor Responses -- Manipulating TNF Receptors to Enhance Tumor Immunity for the Treatment of Cancer.